15:47 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) In vitro and cell culture studies identified two thiazolidinedione-based dual inhibitors of tau-aggregation and GSK3B that could help treat AD. Chemical synthesis and in vitro testing in enzymatic activity assays of 35...
19:57 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Janssen's esketamine meets in Phase III to prevent treatment-resistant depression relapse

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) said intranasal esketamine (formerly JNJ-54135419) plus an oral antidepressant met the primary endpoint of delaying time to relapse during maintenance treatment compared with an oral...
19:23 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Janssen reports long-term safety data for esketamine in treatment-resistant depression

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) reported data from the Phase III SUSTAIN-2 long-term safety study evaluating intranasal esketamine (formerly JNJ-54135419) plus an oral antidepressant to treat treatment-resistant depression showing there...
19:15 , Jun 22, 2018 |  BC Week In Review  |  Financial News

IPO roundup: Avrobio, Aptinyx, Magenta, Kezar, Xeris

Five biopharmas priced IPOs late on June 20, raising a total of more than $460 million. Four of the five upsized their offerings to sell more shares than anticipated; one of those, Avrobio, also priced...
04:46 , Jun 21, 2018 |  BC Extra  |  Financial News

Four companies in IPO quintet post first-day gains

Four of the five biopharmas that priced IPOs late Wednesday posted gains on Thursday. Cell therapy company Avrobio Inc. (NASDAQ:AVRO) had the biggest first-day bump, climbing $12.20 (64%) to $31.20, while three others posted double-digit...
18:33 , May 25, 2018 |  BC Week In Review  |  Financial News

Aptinyx proposes $80M IPO

Neurology company Aptinyx Inc. (Evanston, Ill.) proposed to raise $80 million on May 23 in an IPO on NASDAQ underwritten by J.P. Morgan, Cowen, Leerink and BMO Capital Markets. The company expects data in 1H19 from...
23:14 , May 23, 2018 |  BC Extra  |  Financial News

Aptinyx proposes $80M IPO

Neurology company Aptinyx Inc. (Evanston, Ill.) proposed to raise $80 million in an IPO on NASDAQ underwritten by J.P. Morgan, Cowen, Leerink and BMO Capital Markets. The company expects data in 1H19 from a pair of...
17:27 , May 11, 2018 |  BC Week In Review  |  Clinical News

J&J reports mixed Phase III data of esketamine for depression

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) reported mixed data from two double-blind, international Phase III trials evaluating intranasal esketamine (formerly JNJ-54135419) to treat treatment-resistant depression. The NMDA receptor antagonist met the...
22:40 , May 7, 2018 |  BC Extra  |  Clinical News

Mixed data for J&J's antidepressant in Phase III trials

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) reported mixed data from two Phase III trials testing intranasal esketamine (formerly JNJ-54135419) in patients with treatment-resistant depression. The NMDA receptor antagonist met the primary...
19:57 , May 3, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: April 2018

New Therapeutic Targets and Biomarkers: April 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during April 2018. Therapeutic targets are defined as any protein, gene or other molecule...